MITA Concerned about USPSTF Draft Recommendations for Breast Cancer Screening


Washington, D.C. – The Medical Imaging & Technology Alliance (MITA) today expressed concern with the U.S. Preventive Services Task Force (USPSTF) draft recommendations for breast cancer screening.

“Access to mammography is essential for early detection and treatment of breast cancer,” said Peter Weems, MITA’s Director of Policy. “MITA is concerned that the latest USPSTF draft recommendations will cause confusion about appropriate screening protocols and associated risk. Adoption of these draft recommendations would also create additional cost barriers for women who would be faced with higher cost-sharing for routine mammograms.”

Additionally, the proposal threatens to postpone cancer detection to a later stage when the disease may be more difficult to treat and likely more costly overall.

Further, MITA wishes to ensure that these draft recommendations are based on the latest and most robust data available.


The Medical Imaging & Technology Alliance (MITA), a division of NEMA, is the collective voice of medical imaging equipment, radiation therapy and radiopharmaceutical manufacturers, innovators and product developers. It represents companies whose sales comprise more than 90 percent of the global market for medical imaging technology. For more information, visit Follow MITA on Twitter @MITAToday.